Why Morgan Health is backing autism care provider Cortica
JP Morgan’s Morgan Health is rounding out its first three years of investing with its seventh investment. The health venture, which the bank launched to get a handle on healthcare costs for ...
View ArticleCradle Bio raises $73M Series B for protein-making AI software
European startup Cradle Bio raised a $73 million Series B round, fueling its plans to sell its AI-based protein-making software to more drugmakers. Cradle was founded in December 2021 by a team ...
View ArticleRoche’s TIGIT drug misses overall survival endpoint in Phase 3 lung cancer trial
Roche’s TIGIT drug has failed to clear the final hurdle in a late-stage cancer trial in what’s proving to be a mostly disappointing year for a drug class that was once seen as the next ...
View ArticleRoche buys out CAR-T partner Poseida for $1B upfront
Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning. The Basel-based pharma giant will pay $9 per share in upfront cash, giving...
View ArticleAmgen’s once-a-month obesity shot shows 20% weight loss after a year
Amgen’s long-anticipated weight loss data are here, with MariTide spurring an average of 20% weight loss after one year for patients who are overweight or obese. The company said Tuesday morning ...
View ArticleAviceda aims to raise $200M; Nerviano gets back rights to PARP1 inhibitor
Plus, news about Maat Pharma, Secretome Therapeutics, 35Pharma, Medigene and Doron Therapeutics: Aviceda Therapeutics’ $200M financing: The Boston-area biotech is looking to raise a $200 million equity...
View ArticleAgilent reveals plans to remodel operations as annual revenue dips
CDMO and laboratory product developer Agilent Technologies has unveiled a reshuffle its business model, which will see the consolidation of operations and build up new business priorities. These moves...
View ArticleSoleno’s rare pediatric disease drug faces PDUFA delay by three months
Soleno Therapeutics may have to wait longer to hear from the FDA on the potential approval of its first medicine. The California biotech said Tuesday the agency extended the review period ...
View ArticleFood allergy biotech Alladapt closes after Phase 3 talks with FDA
Alladapt Immunotherapeutics, a well-financed biotech working in the food allergy field, shut down following talks with the FDA, according to a source familiar with the company. After claiming success...
View ArticleSarepta, Arrowhead take a big swing on siRNA drugs for rare disease
Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of biobucks in recent years. The deal, announced Tuesday morning, will see...
View ArticleAxsome moves toward NDA filing for narcolepsy drug after Phase 3 data
Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically significant improvement in the frequency of cataplexy attacks in narcoleptic...
View ArticleThe Biden administration wants Medicare and Medicaid to cover GLP-1s. Will...
The Biden administration proposed a new rule Tuesday that would expand Medicare and Medicaid coverage of popular obesity drugs, earning praise from the pharmaceutical industry and patient advocates....
View ArticleTrump picks Stanford academic and pandemic critic Bhattacharya for NIH
President-elect Donald Trump tapped two policy and political outsiders to fill the remaining top healthcare roles in his administration, including Jay Bhattacharya, a prolific critic of the US Covid-19...
View ArticleIdorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway
Idorsia is making moves to stretch its cash reserves further. The Swiss drugmaker said it is narrowing its operations with 270 positions at risk of elimination. The potential layoffs will most likely...
View ArticleAcadia snaps up an essential tremor drug after field's summer setbacks
A few weeks after gaining about $100 million from a priority review voucher, Acadia Pharmaceuticals is putting its money to work by in-licensing an experimental essential tremor medicine. The San Diego...
View ArticlePTC reports Phase 2 ALS fail, sells priority review voucher for $150M
PTC Therapeutics is staying busy ahead of the Thanksgiving holiday. On Tuesday afternoon, the company announced that a Phase 2 trial evaluating its experimental ALS drug utreloxastat failed on the...
View ArticleNorbert Bischofberger's time as Kronos CEO ends as biotech seeks new life
Kronos Bio is letting go nearly all its employees after flashing red lights earlier this month. As part of an 83% workforce downsizing, CEO Norbert Bischofberger is heading out the door and handing the...
View ArticleBristol Myers sues the federal government over 340B, following other drugmakers
Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model for distributing 340B drug discounts. Under the drugmaker's plan, hospitals...
View ArticleRecursion reduces workforce; Oxford Nanopore teams up with UK Biobank
Plus, news about Portage Biotech: Recursion’s layoffs: After merging with fellow AI-driven biotech Exscientia this fall, Recursion Pharmaceuticals laid off less than 20% of the combined company, a...
View ArticleOutlook's shares crash as wet AMD drug flunks Phase 3 test
After the FDA rejected Outlook Therapeutics’ ophthalmic formulation of bevacizumab last year, the experimental therapy has now failed a late-stage study in patients with a degenerative eye disease. In...
View Article